These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

641 related articles for article (PubMed ID: 27157411)

  • 1. Vaccine technologies: From whole organisms to rationally designed protein assemblies.
    Karch CP; Burkhard P
    Biochem Pharmacol; 2016 Nov; 120():1-14. PubMed ID: 27157411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine adjuvants: current challenges and future approaches.
    Wilson-Welder JH; Torres MP; Kipper MJ; Mallapragada SK; Wannemuehler MJ; Narasimhan B
    J Pharm Sci; 2009 Apr; 98(4):1278-316. PubMed ID: 18704954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioconjugation Approaches to Producing Subunit Vaccines Composed of Protein or Peptide Antigens and Covalently Attached Toll-Like Receptor Ligands.
    Xu Z; Moyle PM
    Bioconjug Chem; 2018 Mar; 29(3):572-586. PubMed ID: 28891637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subunit vaccines of the future: the need for safe, customized and optimized particulate delivery systems.
    Foged C
    Ther Deliv; 2011 Aug; 2(8):1057-77. PubMed ID: 22826868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of size on particulate vaccine adjuvants.
    Shah RR; O'Hagan DT; Amiji MM; Brito LA
    Nanomedicine (Lond); 2014 Dec; 9(17):2671-81. PubMed ID: 25529570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving vaccine performance with adjuvants.
    Vogel FR
    Clin Infect Dis; 2000 Jun; 30 Suppl 3():S266-70. PubMed ID: 10875797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Particulate vaccines: on the quest for optimal delivery and immune response.
    De Temmerman ML; Rejman J; Demeester J; Irvine DJ; Gander B; De Smedt SC
    Drug Discov Today; 2011 Jul; 16(13-14):569-82. PubMed ID: 21570475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in peptide-based subunit nanovaccines.
    Skwarczynski M; Toth I
    Nanomedicine (Lond); 2014 Dec; 9(17):2657-69. PubMed ID: 25529569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulation and stabilization of recombinant protein based virus-like particle vaccines.
    Jain NK; Sahni N; Kumru OS; Joshi SB; Volkin DB; Russell Middaugh C
    Adv Drug Deliv Rev; 2015 Oct; 93():42-55. PubMed ID: 25451136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution, benefits, and shortcomings of vaccine management.
    McCullers JA
    J Manag Care Pharm; 2007 Sep; 13(7 Suppl B):S2-6. PubMed ID: 17874877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harnessing self-assembled peptide nanoparticles in epitope vaccine design.
    Negahdaripour M; Golkar N; Hajighahramani N; Kianpour S; Nezafat N; Ghasemi Y
    Biotechnol Adv; 2017 Sep; 35(5):575-596. PubMed ID: 28522213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biotechnology approaches to produce potent, self-adjuvanting antigen-adjuvant fusion protein subunit vaccines.
    Moyle PM
    Biotechnol Adv; 2017; 35(3):375-389. PubMed ID: 28288861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of synthetic peptidic constructs for the vaccine development against viral infections.
    Haro I; Gómara MJ
    Curr Protein Pept Sci; 2004 Dec; 5(6):425-33. PubMed ID: 15581414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-clinical safety evaluation of novel vaccines and adjuvants: new products, new strategies.
    Brennan FR; Dougan G
    Vaccine; 2005 May; 23(24):3210-22. PubMed ID: 15837222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Subunit vaccines--antigens, carriers, conjugation methods and the role of adjuvants].
    Jarząb A; Skowicki M; Witkowska D
    Postepy Hig Med Dosw (Online); 2013 Nov; 67():1128-43. PubMed ID: 24379254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Designer adjuvants for enhancing the efficacy of infectious disease and cancer vaccines based on suppression of regulatory T cell induction.
    Mills KH
    Immunol Lett; 2009 Feb; 122(2):108-11. PubMed ID: 19100777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoparticle Vaccines Against Infectious Diseases.
    Pati R; Shevtsov M; Sonawane A
    Front Immunol; 2018; 9():2224. PubMed ID: 30337923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modern Vaccines/Adjuvants Formulation Session 6: Vaccine &Adjuvant Formulation & Production 15-17 May 2013, Lausanne, Switzerland.
    Fox CB
    Hum Vaccin Immunother; 2013 Sep; 9(9):2007-8. PubMed ID: 23787558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine development: from empirical medicine to molecularly designed therapy.
    Buschle M; Mattner F; Zauner W; von Gabain A
    Biol Chem; 2001 Apr; 382(4):505. PubMed ID: 11405215
    [No Abstract]   [Full Text] [Related]  

  • 20. Type III hypersensitivity reactions to a B cell epitope antigen are abrogated using a depot forming vaccine platform.
    MacDonald LD; MacKay A; Kaliaperumal V; Weir G; Penwell A; Rajagopalan R; Langley JM; Halperin S; Mansour M; Stanford MM
    Hum Vaccin Immunother; 2018 Jan; 14(1):59-66. PubMed ID: 28933663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.